PMA
4-methoxyamphetamine
Viewing r1 — Apr 25, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
PMA (para-methoxyamphetamine) is a synthetic empathogen of the phenethylamine class. It is related to MDMA but distinguished by an additional ability to block the enzyme that breaks serotonin down. These simultaneous actions — releasing serotonin, blocking reuptake, and preventing breakdown — produce serotonin accumulation far beyond what MDMA generates.[1][2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MDMA, PMMA, MDA +1 moreMDMA, PMMA, MDA, 4-MTA show less
First described circa 1946,citation needed PMA entered illicit drug markets around 1970, sold as a substitute for MDA and LSD. Nine deaths in Ontario in 1973 prompted rapid scheduling in the US and UK.[4] Today PMA persists in the ecstasy supply almost exclusively as an adulterant or mislabeled MDMA tablet, carrying the highest drug control classification in virtually every country where it appears.
Subjective effects include moderate stimulation, emotional warmth, anxiety, and mild visual disturbances.[5] The experience is less rewarding and more physically punishing than MDMA — the emotional openness is muted and cardiovascular strain is pronounced.[6] Nausea, agitation, and dangerous overheating are characteristic unsought effects.
PMA shows low abuse liability[7] but extreme acute toxicity — the margin between an active and a fatal dose is among the narrowest of any recreational substance.[8] A slow onset — 60–90 minutes or longer — leads users to redose before the first takes hold, producing lethal serotonin overload and overheating.[9][6] No clinical trials have been conducted; the evidence base is forensic cases, animal studies, and laboratory pharmacology.
History[edit]
Discovery
PMA was first described circa 1946citation needed and drew little scientific attention until the early 1970s, when it appeared on illicit markets as a substitute for MDA and LSD. US deaths were first reported in 1972, followed by nine fatalities among young users in Ontario, Canada, between March and August 1973.[4]
Prohibition and death clusters
The Ontario deaths prompted rapid scheduling: the US listed PMA as Schedule I in September 1973[10] and the UK followed in 1977.[11] PMA largely vanished during the 1980s, then resurfaced in South Australia in the early 1990s — again sold as MDMA — earning the street name "death".[12][13]
Modern resurgences
Fatality clusters continued: roughly 20 deaths worldwide between 2000 and 2001,[4] 12 fatal intoxications in Norway in 2010–2011,[14] and 29 deaths in England and Wales in 2013.[4] PMA persists because its key precursor, anethole — derived from cheap anise oil — is largely uncontrolled.[15]
The name para-methoxyamphetamine describes the compound's defining structural feature: a methoxy group at the para position of the amphetamine phenyl ring. The abbreviation PMA and the alternate designation 4-MA are used interchangeably in scientific and forensic literature.
Chemistry[edit]
Structural class
PMA belongs to the phenethylamine chemical family — the same broad class as MDMA, MDA, and standard amphetamine.
The single feature that sets it apart is a methoxy group attached to the para position of the phenyl ring; this substitution is responsible for PMA's unusual pharmacological profile. PMA is also a metabolite of PMMA[16] — the body produces it when breaking PMMA down.
Molecular properties
| Molecular formula | C₁₀H₁₅NO |
| Molecular weight | 165.23 g/mol |
Pharmacology[edit]
Mechanism of action
PMA elevates brain serotonin through three simultaneous actions: it releases serotonin into the synapse, blocks its reuptake, and inhibits MAO-A — the enzyme that normally breaks serotonin down.[1][2][3] The combined result is serotonin accumulation far beyond what any single mechanism produces. PMA also releases dopamine and norepinephrine,[17] contributing to its stimulant character.
Pharmacological classification
PMA has been described as both a serotonergic entactogen[18] and a hallucinogen based on animal behavioral studies,[5] with partial cross-generalization to LSD in drug discrimination tests.[19] The US DEA classifies it as a Schedule I hallucinogen.[10]
Pharmacokinetics
Oral onset is 60–90 minutes or longer — far slower than MDMA.[9][8][4] This delay is the central factor in PMA's danger: users frequently take a second dose before the first takes hold. No controlled human pharmacokinetic data — half-life, bioavailability — have been published.
Neuroscience[edit]
Where it acts
PMA floods multiple brain regions with serotonin. In the striatum it rises to roughly 360% of baseline; in the substantia nigra, over 700%.[2][20] Hot environments dramatically amplify this — at 30°C versus 22°C, serotonin output combined with a monoamine oxidase inhibitor nearly quintupled.[21]
Why it matters
When serotonin release, reuptake blockade, and metabolic blockade all operate simultaneously, the brain's temperature regulation fails catastrophically.[20] This is why PMA is more dangerous than substances that elevate serotonin through only one or two pathways. Repeated exposure reduces SERT availability by 53%,[22] but without the structural nerve damage seen with MDMA.[23]
Subjective Effects[edit]
PMA produces a diffuse emotional warmth and physical stimulation, but both are overlaid with cardiovascular strain and a persistent bodily heaviness.[6][3] Hot, crowded environments sharply amplify both the subjective intensity and the physiological risk.[21] The experience is defined as much by physical discomfort as by any empathogenic quality.
Compared to MDMA, PMA delivers less euphoria and less emotional closeness, with more pronounced body load.[6] Users who have taken both describe PMA as less rewarding and more punishing — the warmth is present, but muted, and the physical cost is amplified.
Effect Grid
The full subjective profile manifests: moderate stimulation, emotional warmth and feelings of closeness, heightened sensory perception, and possible visual disturbances consistent with PMA's partial hallucinogenic classification. Cognitive euphoria and prosocial effects reach their clearest expression.
Physical effects intensify: tachycardia, elevated blood pressure, sweating, bruxism, and pupil dilation become pronounced. Body temperature begins to rise noticeably. Nausea and dizziness may occur. Duration extends to an estimated 6–8+ hours.
At this range, PMA's narrow therapeutic window becomes critically relevant. Any additional dosing risks crossing into dangerous territory. Hot environments and physical exertion amplify hyperthermia risk.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual drifting · Tracers · Visual haze / noise
Pupil dilation · Wakefulness · Dehydration sensation · Vasoconstriction · Dry mouth · Heart rate perception changes · Restlessness · Body high · Insomnia · Muscle tension · Physical fatigue · Respiratory stimulation · Dizziness · Nausea · Headache · Trembling · Seizure threshold reduction · Bruxism · Sexual arousal suppression · Motor control impairment · Nystagmus (eye wobbles) · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Vomiting · Involuntary body movements
Dry mouth · Heart rate perception changes · Restlessness · Body high · Insomnia · Muscle tension · Physical fatigue · Respiratory stimulation · Dizziness · Nausea · Headache · Trembling · Seizure threshold reduction · Bruxism · Sexual arousal suppression · Motor control impairment · Nystagmus (eye wobbles) · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Vomiting · Involuntary body movements
Cognitive impairment · Confusion · Analysis enhancement · Focus enhancement · Information processing enhancement · Motivation enhancement · Aesthetic enhancement · Cognitive dysphoria · Decision impairment · Thought disorganization · Thought loops · Delirium
Focus enhancement · Information processing enhancement · Motivation enhancement · Aesthetic enhancement · Cognitive dysphoria · Thought disorganization · Thought loops · Delirium
Emotional enhancement · Empathy enhancement · Irritability · Anhedonia · Emotional lability · Mania
Anhedonia · Emotional lability
Communication enhancement · Craving · Emotional susceptibility · Trust enhancement
Timeline
First alerts are subtle and delayed — mild restlessness or slight mood shift. This prolonged onset (60–120 minutes) is the defining danger: users accustomed to MDMA's 30–60 minute onset frequently re-dose during this window.
Stimulation builds gradually with emerging emotional warmth and sensory enhancement. Tachycardia, pupil dilation, and jaw tension become noticeable. Rising body temperature begins.
Maximum stimulation, emotional intensity, and sensory effects. Hyperthermia risk is highest during this phase. Visual disturbances and prosocial effects are most pronounced.
Effects sustain at diminishing intensity. Stimulation and emotional effects persist but begin to recede. Physical discomfort (jaw tension, temperature dysregulation) may become more prominent as subjective reward diminishes.
Gradual return toward baseline over 1–2 hours. Residual stimulation, fatigue, and emotional flatness. Appetite remains suppressed.
Residual effects include fatigue, mood depression, irritability, appetite suppression, and difficulty concentrating. Sleep may remain disrupted for several hours.
⚠ Avoid driving or operating machinery for at least 12 hours after effects begin to subside, as residual impairment and fatigue persist beyond subjective resolution.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- MDMA · PMMA · MDA
Toxicity
Acute toxicity
PMA is among the most acutely dangerous substances found in the ecstasy supply. Fatal blood concentrations begin as low as 0.57 mg/L in polydrug cases,[8][24][25] and it is consistently more toxic than MDMA at equivalent doses.[3][6]
PMA is among the most dangerous substances encountered in the ecstasy/MDMA supply. The narrow margin between active and lethal doses, combined with delayed onset that promotes re-dosing, creates an acute overdose risk not present with MDMA itself.
Documented causes of death include:
- Hyperthermia: Core body temperature exceeding 40–42°C[9][26][6]
- Cardiovascular collapse: The most frequently recorded cause of death in forensic studies[8][13][24]
- Seizures: Generalized convulsions in multiple fatal and near-fatal cases[9][14]
- Multi-organ failure: Including muscle breakdown, kidney failure, liver failure, and blood clotting dysfunction[24][27][26]
- Respiratory failure[14]
Serotonin syndrome
PMA poisoning presents like serotonin syndrome — high body temperature, muscle rigidity, agitation, rapid heart rate, and heavy sweating. PMA and PMMA exposure has been documented to cause multi-organ failure and cardiovascular collapse through this mechanism.[27]
Electrolyte disturbances
Low blood sugar and high potassium levels appear specific to PMA poisoning and may represent independent risk factors in fatal cases.[9]
Muscle breakdown
Amphetamine-class intoxication causes muscle breakdown in approximately 30% of cases.[28] PMA-specific rates have not been separately documented but are expected within or above this range given its more severe serotonergic toxicity.
Psychological Risks
PMA causes dose-dependent anxiety and agitation.[26] Comedown effects include irritability, low mood, sleep disruption, appetite suppression, concentration difficulties, and paranoia.[26] The dominant psychological danger is the acute serotonergic crisis, not long-term psychiatric effects.
Tolerance & Dependence
Tolerance
Repeated PMA use reduces SERT availability by 53%.[22] This could reduce effects over time and drive dose escalation — a particularly dangerous pattern given the narrow margin between active and lethal doses. No human tolerance data exist.citation needed
Dependence
PMA does not sustain self-administration in rats and shows only weak similarity to amphetamine in drug discrimination tests.[7][29] Physical withdrawal has not been documented.[26]
Drug Interactions
PMA's triple serotonergic mechanism makes it exceptionally dangerous with any substance that further elevates serotonin, cardiovascular strain, or body temperature.
MAO inhibitor combinations
PMA is itself a potent MAO-A inhibitor.[1] Adding any external monoamine oxidase inhibitor — moclobemide, phenelzine, or tranylcypromine — compounds the blockade. At elevated temperature (30°C), the combination of PMA and moclobemide produced 1450% peak serotonin elevation and sustained dangerous overheating.[21][2]
Serotonergic drugs
Tramadol, SSRIs, and SNRIs carry severe serotonin syndrome risk when combined with PMA.safety citation needed MDMA combined with PMA appears in multiple fatalities[24][30] — PMA's slow onset means users may unknowingly combine both when they redose.
Stimulants
Cocaine, methamphetamine, and other stimulants add cardiovascular strain and hyperthermia risk when combined with PMA.[26]
Cannabis and alcohol
Cannabis may increase anxiety and paranoia. Alcohol amplifies negative effects.[26] No pharmacokinetic interaction data exist for either combination.
Contraindications
Concurrent MAO inhibitor therapy — including moclobemide, phenelzine, tranylcypromine, or selegiline — is an absolute contraindication. The combination dramatically amplifies serotonin syndrome risk and can be lethal at any PMA dose.[2][21]
Cardiovascular conditions — high blood pressure, heart rhythm disorders, structural heart disease — are absolute contraindications given documented cardiovascular collapse as a mechanism of death.[26]
Epilepsy is contraindicated given documented seizures in PMA poisoning.[9][14]
Respiratory conditions are relative contraindications given respiratory failure as a documented mechanism of death.[26]
Liver and kidney impairment are relative contraindications given multi-organ failure in severe toxicity and likely hepatic metabolism of PMA.[16]
Harm Reduction[edit]
Forms & Identification
PMA is almost never sold under its own name. It appears in tablets marketed as MDMA or ecstasy, often with branding identical to known pill designs — including logos linked to fatality clusters such as "Red Mitsubishi" and Rolex crown stamps.[4]
Reagent testing is essential. PMA reacts differently from MDMA with standard field kits, making it identifiable before ingestion. Drug checking services, where available, provide the most reliable identification and should be used whenever possible.
Guidelines
- Test every tablet or powder with reagent kits before use — PMA is visually indistinguishable from MDMA
- Start with the lowest possible dose and do not redose for at least 2–3 hours — PMA's onset is far slower than MDMA
- Use in cool environments with good ventilation; avoid crowded, hot venues
- Stay hydrated but do not overdrink — sip water steadily rather than consuming large amounts
- Have a sober, informed companion present who knows what was taken and when
- Monitor body temperature; if skin feels unusually hot to the touch, begin active cooling immediately
- Know the location of the nearest medical facility before the session begins
Set & Setting
Hot, crowded venues — nightclubs, festivals — dramatically increase lethal hyperthermia risk by amplifying PMA's disruption of temperature regulation.[21][6] Cool environments with access to water and ventilation substantially reduce physiological danger.
PMA's delayed onset (60–120+ minutes) means effects may not appear until well into an event. The single most documented pathway to PMA fatality is taking a second dose because the first seemed not to have worked.[26]
Aftercare & integration. PMA produces a significant physical and psychological comedown. Expect fatigue, irritability, low mood, disrupted sleep, and reduced appetite in the days following use.[26] These effects reflect serotonin depletion and typically resolve within a week.
Prioritize sleep, nutrition, and gentle physical activity during recovery. Avoid all serotonergic substances — including MDMA, other empathogens, and serotonergic medications — for at least several weeks. If anxiety, depression, or paranoia persist beyond 7–10 days, seek professional support.
Recovery & Support
PMA carries low abuse liability — it is not typically a substance of compulsive use.[7] Repeated exposure more commonly results from its presence as an MDMA adulterant than from intentional seeking. However, patterns of escalating empathogen or stimulant use warrant attention.
Support resources include local drug and alcohol services, national helplines, and peer support groups. Drug checking services can reduce harm by identifying PMA before consumption.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Body temperature that can be felt radiating through clothing. Rigid or jerking muscles. Seizure. Loss of consciousness. Rapid or irregular heartbeat. Confusion or agitation that escalates rather than resolves. Any of these after taking a substance believed to be MDMA demands immediate medical attention.
Immediate steps:
- 1. Call emergency services immediately — PMA toxicity escalates rapidly and cannot be managed without medical intervention
- 2. Move the person to the coolest available environment
- 3. Remove excess clothing and apply cool (not ice-cold) water to skin, especially neck, armpits, and groin
- 4. Place an unconscious person in the recovery position (on their side, airway clear)
- 5. Do not induce vomiting
- 6. Do not give aspirin or paracetamol — these do not treat drug-induced hyperthermia and may worsen organ damage
- 7. Stay with the person until help arrives
What to tell the dispatcher: Name the substance (PMA or ecstasy/MDMA), estimated amount and time taken, and current symptoms — especially body temperature, seizures, or loss of consciousness. Good Samaritan laws in many jurisdictions protect people who call for help during drug emergencies.
Legal Status[edit]
PMA carries the highest level of drug control in virtually every jurisdiction where it has been specifically scheduled, listed under Schedule I of the UN Convention on Psychotropic Substances. It was among the earliest substituted amphetamines to be controlled, following documented fatalities in both the US (1973) and UK (1977).
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Classified as a hallucinogen. Effective September 21, 1973[10] |
| United Kingdom | Class A, Schedule 1 (Misuse of Drugs Act 1971) | Controlled under phenethylamine structural clause. Effective September 20, 1977[11] |
| Australia | Schedule 9 (Prohibited Substance) | Poisons Standard[26] |
| Germany | Highest control level (BtMG) | Controlled since September 1999[31] |
| Canada | Schedule I (CDSA) | Added in 2012 following documented fatalities[31] |
| New Zealand | Class A (Misuse of Drugs Act) | Highest classification[31] |
| International | Schedule I (UN Convention on Psychotropic Substances) | No accepted medical use; highest international control level |
Legal status varies by jurisdiction and changes over time. The information above reflects available records and is not legal advice. Verify current status with local legal resources before relying on it.
references
- [1] ^abcGreen AL, El Hait MA (1980) p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. — The Journal of Pharmacy and Pharmacology PMID:6103055
- [2]
- [3] ^abcdCallaghan PD, Irvine RJ, Daws LC (2005) Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry. — Neurochemistry International PMID:15979209
- [4]
- [5] ^abHegadoren KM, Martin-Iverson MT, Baker GB (1995) Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine. — Psychopharmacology PMID:7617822
- [6]